Article Information
History
- April 7, 2022.
Article Versions
- Version 1 (January 5, 2022 - 11:12).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- aNune Eye Hospital, Seoul, Korea
- bCollege of Letters & Science, University of Wisconsin-Madison, Madison, WI 53715
- cBrain and Cognitive Sciences Research Center, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea
- dDepartment of Medicine and Medical Microbiology, School of Medicine, New Tokyo Medical College, Pohnpei, FM 96941
- eDepartment of Ophthalmology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, South Korea
- ↵*Corresponding author: Prof. Dr. Sung Jin Lee, Department of Ophthalmology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, 59 Daesagwan-ro, Seoul 04401, South Korea, Tel: +82-2-709-9114, Email: mirotinclinicaltrials{at}gmail.com
↵1 Both authors contributed equally to this work.
Posted April 07, 2022.
A nonrandomized phase 2 trial of EG-Mirotin, a novel, first-in-class, subcutaneously delivered peptide drug for non-proliferative diabetic retinopathy
